Ralaniten Explained

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]

See also

Notes and References

  1. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD . 6 . An androgen receptor N-terminal domain antagonist for treating prostate cancer . The Journal of Clinical Investigation . 123 . 7 . 2948–2960 . July 2013 . 23722902 . 3696543 . 10.1172/JCI66398 .
  2. Monaghan AE, McEwan IJ . A sting in the tail: the N-terminal domain of the androgen receptor as a drug target . Asian Journal of Andrology . 18 . 5 . 687–694 . 2016 . 27212126 . 5000789 . 10.4103/1008-682X.181081 . free .
  3. Maughan BL, Antonarakis ES . Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer . Current Treatment Options in Oncology . 16 . 12 . 57 . December 2015 . 26537882 . 10.1007/s11864-015-0375-z . 30398927 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ralaniten".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.